KA צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Kineta Bio

Kineta, Inc. is fighting to maintain its scientific potential amid acute funding shortages and intense competition. Simultaneously, the company adheres to bioethical norms and environmental production standards. The quarterly EPS growth confirms the current trend, where the metric is held at 0.00. Currently, the business's financial stability relies exclusively on external financing and grants due to a lack of recurring revenue.

Kineta, Inc. focuses on developing breakthrough immuno-oncology drugs for the treatment of resistant forms of cancer by targeting the VISTA pathway. The quarterly EPS growth trajectory, stripped of market noise through daily recalculation, measures the real dynamics of net income per share, allowing for an assessment of the business's financial stability and the determination of the fair value of capital amid a sideways trend.